Citation: Lin Kooi Ong, Frederick Rohan Walker, Michael Nilsson. Is Stroke a Neurodegenerative Condition? A Critical Review of Secondary Neurodegeneration and Amyloid-beta Accumulation after Stroke[J]. AIMS Medical Science, 2017, 4(1): 1-16. doi: 10.3934/medsci.2017.1.1
| [1] | Shifan Xie, Yik Roy Hwang, Revin Thomas . Hyperacute management of ischemic strokes, a British perspective. AIMS Medical Science, 2023, 10(2): 107-117. doi: 10.3934/medsci.2023009 |
| [2] | Brandon M. Jones, E. Murat Tuzcu, Amar Krishnaswamy, Samir R. Kapadia . Incidence and Prevention of Strokes in TAVI. AIMS Medical Science, 2015, 2(1): 51-64. doi: 10.3934/medsci.2015.1.51 |
| [3] | Ola Shawky, Maha Alkhaldi, Deema Yousef, Adnan Alhindi, Teef Alosaimi, Amjad Jawhari, Aliah Aladwani . Incidence of first-time stroke in Taif, Saudi Arabia. AIMS Medical Science, 2022, 9(2): 293-303. doi: 10.3934/medsci.2022012 |
| [4] | Marie-Louise Bird, Janice J Eng, Brodie M. Sakakibara . Predicting interest to use mobile-device telerehabilitation (mRehab) by baby-boomers with stroke. AIMS Medical Science, 2018, 5(4): 337-347. doi: 10.3934/medsci.2018.4.337 |
| [5] | Ayşegül Çelik, Belgüzar Kara . The relationship between the stroke survivors’ functional status and their informal caregivers’ burden and quality of life. AIMS Medical Science, 2019, 6(1): 115-127. doi: 10.3934/medsci.2019.1.115 |
| [6] | Ayema Haque, Areeba Minhaj, Areeba Ahmed, Owais Khan, Palvisha Qasim, Hasan Fareed, Fatima Nazir, Ayesha Asghar, Kashif Ali, Sobia Mansoor . A meta-analysis to estimate the incidence of thromboembolism in hospitalized COVID-19 patients. AIMS Medical Science, 2020, 7(4): 301-310. doi: 10.3934/medsci.2020020 |
| [7] | Hirmand Nouraei MASc, Anna M. Chudyk, Wendy L. Cook, Pierre Guy, Penny Brasher, Joseph H. Puyat, Maureen C Ashe . Recovery of physical function after hip fracture: Analysis of secondary outcomes from a randomized controlled trial. AIMS Medical Science, 2018, 5(3): 268-283. doi: 10.3934/medsci.2018.3.268 |
| [8] | Elżbieta Marczak, Maria Szarras-Czapnik, Małgorzata Wójcik, Agata Zygmunt-Górska, Jerzy Starzyk, Karolina Czyżowska, Anna Szymańska, Katarzyna Gołąb-Jenerał, Agnieszka Zachurzok, Elżbieta Moszczyńska . Hypopituitarism—A rare manifestation in Joubert syndrome: about 4 cases. AIMS Medical Science, 2024, 11(3): 318-329. doi: 10.3934/medsci.2024022 |
| [9] | Vanessa J. White, Ramesh C. Nayak . Re-circulating Phagocytes Loaded with CNS Debris: A Potential Marker of Neurodegeneration in Parkinsons Disease?. AIMS Medical Science, 2015, 2(1): 26-34. doi: 10.3934/medsci.2015.1.26 |
| [10] | Hong-Yi Chang, Hung-Wen Tsai, Chiao-Fang Teng, Lily Hui-Ching Wang, Wenya Huang, Ih-Jen Su . Ground glass hepatocytes provide targets for therapy or prevention of hepatitis B virus-related hepatocellular carcinoma. AIMS Medical Science, 2018, 5(2): 90-101. doi: 10.3934/medsci.2018.2.90 |
Deficits in motor function and cognition after ischemic stroke are caused by the loss of brain tissue at the occlusion site. Critically, tissue death within the central nervous system does not stop at the border of the infarct and penumbral territories. Although, less researched, death of tissue at the infarction site triggers an insidious and apparently inexorable process known as secondary neurodegeneration (SND). SND involves the progressive death of regions that are anatomically connected to the infarction site but are often quite distal and can, in the short term at least, retain normal vascular supply [1,2]. SND has been consistently observed in clinical neuroimaging studies and in pre-clinical studies at the cellular level (see Table 1). Increasingly, it appears that sites of SND share many pathophysiological of common neurodegenerative diseases, including disturbances in amyloid-β (see Table 2). This observation is of particular interest, given that risk of dementia or cognitive decline is recognised to be dramatically elevated after stroke [3,4].
Given the progressive nature of SND, the presence of pathophysiological features such as altered levels of amyloid-β, and the increased risk of cognitive decline and/or dementia suggest the possibility that stroke initiates a neurodegenerative condition. The major highlight of this review is to specifically consider the presence of amyloid-β and its potential involvement in the SND pathology after stroke. Amyloid-β has already been extensively characterised for its involvement in Alzheimer's disease (AD) [5]. The role of amyloid-β in AD, however, continues to undergo continual expansion and revision (reviewed in [6,7,8,9,10,11,12]). In part this is because amyloid-β possesses a molecular structure that allows it to assume a large variety of configurations within the central nervous system, each of which appears to result in quite distinct biological effects [13,14].
This issue of specificity with respect to configuration state of amyloid-β is not simply academic matter for those concerned with SND after stroke. There have already been several studies to investigate changes in amyloid-β in the brain after stroke, the results of which show low or limited levels of alignment with each other [15,16,17,18,19,20,21]. In part, this misalignment may be attributable to which forms of amyloid-β are being measured and reported on. Failure to recognise this fact may lead to incorrect conclusions being drawn about the significance of amyloid-β over the course of recovery. As such, we will begin this review by giving a brief highlight addressing the basic processes of amyloid-β production, before moving to address the technical approaches used to measure it. We will follow this with an overview of stroke-induced neurodegeneration with a focus on the thalamus and explore the findings from these studies that related to amyloid-β. The overall focus of this review is to conclude whether stroke is a neurodegenerative condition.
Amyloid-β is a peptide of 36 to 43 amino acids and is usually produced in all neurons through sequential proteolytic processing of APP, by β-secretase and γ-secretase. Within the literature there are two primary monomeric amyloid-β isoforms; amyloid-β-40 (Aβ40) and amyloid-β-42 (Aβ42) [9]. Amyloid-β monomers have the propensity to self-assemble into soluble low molecular weight oligomers that can exist in several forms (e.g. dimer, an assembly of 2 monomers, trimer, an assembly of 3 monomers and so on). These low molecular weight oligomers can then form misfolded oligomers (known as "nuclei"), which will increase in size to form soluble high molecular weight oligomers (e.g. dodecamers also known as Aβ*56 [22]), and eventually continue to aggregate to form into insoluble amyloid fibrils (also known as beta-sheets) that deposit in the brain to yield dense core plaques (contain clumps of amyloid fibrils and other substances) (see Figure 1) [14].
Figure 1. The conformational states of amyloid-β. Left panel, amyloid-β monomers self-assemble into low molecular weight oligomers, which increase in size to form higher molecular weight oligomers, and eventually continue to aggregate to form fibrils that deposit within the brain, ultimately yielding dense core plaques. As the amyloid-β aggregates from monomers to plaques, the conformation size increases and the solubility decreases. Right panel, provides an example of the change in oligomerisation status of amyloid-β within the stroked brain. Oligomerisation has been detected using western blotting, comparing amyloid-β within the contralateral (CL) and ipsilateral (IL) thalamus at 6 weeks after stroke. Amyloid-β antibody (D3D2N, #15126, Cell Signaling Technology) detected soluble amyloid-β monomers (~5 kDa), low molecular weight oligomer (10-30 kDa) and high molecular weight oligomers (30-100 kDa).The aggregation of amyloid-β and the eventual formation of plaques in the brain of AD patients has led to the development of the "amyloid hypothesis" [23]. This hypothesis simply holds that the overproduction, decreased clearance and/or enhanced aggregation of amyloid-β disrupt cellular functioning. While emphasis has been placed on dense core amyloid plaques as a primary driver of pathology in the context of AD, emerging literature has indicated that soluble amyloid-β oligomers, rather than the monomers or insoluble fibrils, may be responsible for the cellular pathology [6,7,8]. The soluble amyloid-β oligomers have been shown to permeabilize both cell and mitochondrial membranes and, therefore responsible for calcium dysregulation, membrane depolarization, and impairment of mitochondrial functions [24]. The soluble amyloid-β oligomers have also been shown to inhibit long-term potentiation in the hippocampus and, therefore, induce synaptic dysfunction [25].
The accumulation of amyloid-β in brain tissue has commonly been investigated using histological stains such as Congo Red and Thioflavin T [26]. The original usage of these stains was to identify amyloid fibrils and plaques in vivo and to study amyloid-β aggregation process in vitro. Congo Red and Thioflavin T bind to beta-sheet-rich-amyloid fibrils and undergo spectral shifts to produce fluorescent signals. These stains, however, are not perfectly specific for the detection of other amyloid-β configurations including monomers and soluble oligomers. Therefore there are limits on how generalizable negative results using the stains are to lower molecular weight amyloid-β structures [27].
A more specific and comprehensive way to distinguish different forms of amyloid-β is through the use of amyloid-β antibodies [14]. These antibodies are used immunohistochemically on fixed brain tissue to visualise the distribution and localization of different amyloid-β species. Further, these antibodies have been used with biochemical assays on tissue lysates (such as brain extracts) for the quantitative detection and/or identification of specific amyloid-β species. For instance, antibody-dependent enzyme-linked immunosorbent assay provides information on the levels of specific amyloid-β isoforms and the presence of oligomers, but not specific size. These antibodies have also been used with western blotting to detect the presence of specific amyloid-β oligomers according to size (see Figure 1) [13,14].
Another approach used to study accumulation of amyloid-β in non-invasive imaging studies is the Pittsburgh compound B (PiB). [11C]PiB (PiB is labelled with radioactive carbon 11) is injected intravenously and is then used in combination with positron emission tomography (PET) to detect cerebral amyloid-β plaques. [11C]PiB was first used for imaging AD patients, which exhibited marked retention of [11C]PiB in regions of the brain known to contain large number of amyloid deposits in AD [28]. [11C]PiB has now also been used to detect the amyloid-β accumulation in other neurodegenerative conditions (reviewed in [29]), including stroke [4,18,20,30]. It should be noted that [11C]PiB is recognised to have particularly high binding affinity for amyloid fibrils found in dense core plaques but low binding affinity to soluble oligomers or non-fibril amyloid-β forms [31]. Therefore, [11C]PiB and like Congo Red and Thioflavin T are limited in their ability to detect amyloid-β monomers and soluble oligomers. As such, there is a need to exert caution when interpreting positive and negative signal using [11C]PiB, Congo Red and/or Thioflavin T. Often a combination of antibody-based assays would be required to obtain the most optimal information.
The typical features of neurodegenerative diseases are characterised by the selective and progressive neuronal loss, synaptic alterations and neuroinflammation (in the form of reactive astrogliosis and microgliosis) (reviewed in [32,33]). Another primary histopathological characteristic of neurodegenerative diseases is the presence of cerebral deposits of misfolded protein aggregates, such as amyloid-β (reviewed in [34]). For example, AD is characterised by neuronal loss, extracellular plaques comprising aggregated amyloid-β protein and intracellular neurofibrillary tangles generated by hyperphosphorylated forms of the microtubule-binding protein, tau [5]. Neurodegenerative diseases and stroke are classically characterised in different neurological disorders. They are viewed to be phenotypes of very different forms of neurological disorders; neurodegenerative diseases as a progressive neuronal loss and stroke as an acute vascular injury.
Although stroke is not widely recognised as a neurodegenerative condition, reports of ongoing degenerative changes in remote distal sites of the brain after the initial infarction have long been recorded. Degeneration distal to the infarction site has been most consistently observed in the thalamus. Thalamic disturbances have been shown to emerge within weeks of infarction, irrespective of the occlusion type and persist for several years after stroke using CT [35], MRI [36,37,38], DTI [38,39,40] and PET [41,42,43] after MCA infarction in humans. In experimental models thalamic degeneration has also been observed after MCA occlusion [44,45,46,47,48] or photothrombotic (PT) somatosensory cortex occlusion [49,50,51]. The most dominant histopathological feature of stroke-induced thalamic SND is neuronal loss concomitant with intense glial disturbance (see Figure 2). Table 1 summarizes neuroimaging and histological features of thalamic SND after stroke.
Figure 2. Typical features of thalamic SND at 6 weeks after PT somatosensory cortex occlusion. Immunohistochemistry staining of (A, B) NeuN, a marker for mature neurons, (C, D) GFAP, an astroglial cytoskeletal marker, (E, F) Iba1, a microglial specific cytoskeletal protein marker and (G, H) accumulation of amyloid-β. Scale bars represent 1 mm in low magnifying images and 50 µm in high magnifying images. The infract hemisphere is identified with asterisks (*).As mentioned in the previous section, neurodegenerative diseases are characterised by loss of neurons and malformation of protein conformations in distinct brain regions leading to distinct functional deficits defining clinical presentations. It has been suggested that ischemic brain damage can induce accumulation of amyloid-β in the human brain [16,30], and has been further supported by rodent studies describing the accumulation of amyloid-β in thalamic SND after MCA stroke or PT stroke [15,17,21]. There is, however, some inconsistency between these rodent, human [18,20] and non-human primate [19] findings.
Only a few human studies have attempted to directly investigate the accumulation of amyloid-β at sites of thalamic SND after stroke. Amongst the first, was a large post-mortem study of 484 patient brains with cerebrovascular lesions [16]. The cerebrovascular lesions were classified as intra- or extra-axial and ischemic or haemorrhagic. Fixed post-mortem brain sections within the parietal cortex and thalamus from non-affected side lacking infarcts were immunohistochemically labelled with amyloid-β, Aβ40 and Aβ42. Amyloid-β accumulation was detected in the parietal cortex of 168 (34%) subjects and in the thalamus of 120 (25%) subjects.
Recently, three studies, to our knowledge, have examine amyloid-β after ischemic stroke using PET imaging of [11C]PiB. The first study by Ly et al. examined the accumulation of [11C]PiB within the peri-infarct region of 21 patients within 30 days after stroke [18]. The authors identified that [11C]PiB retention in the peri-infarct region was higher relative to the contralateral hemisphere. No differences in [11C]PiB retention were observed elsewhere in the brain. The second study by Liu et al. examined global cerebral accumulation of [11C]PiB and the association of amyloid-β accumulation with cognitive changes over time [30]. The study involved 72 patients with cognitive impairment after stroke. The baseline cognitive assessment was performed on the patients at 3 to 6 months after stroke and the patients returned for annual follow-up over 3 years. [11C]PiB PET scanning was performed only once at 11.6 ± 7.4 months post baseline cognitive assessment. The authors observed that not all patients presented with high levels of [11C]PiB retention. There was, however, a robust and statistically significant positive correlation between higher levels of [11C]PiB retention and cognitive decline. The third study by Sahathevan et al. examined [11C]PiB accumulation in 47 ischemic stroke patients [20]. The primary comparison involved comparing [11C]PiB retention in the peri-infarct region to a reference region in the undamaged hemisphere, no differences were observed between these regions. Further, the authors observed no evidence of [11C]PiB accumulation in the ipsilateral hemisphere of 21 patients over 18 months after stroke. Sahathevan et al. attributed the misalignment of their results to those reported earlier by Ly et al. to a number of issues including the use of a larger sample size and more accurate definitions of the infarct and non-infarcted zones. On the basis of these results the authors proposed that ischemic stroke does not result in increased or sustained accumulation of amyloid-β within the brain.
In rodent studies, the accumulation of amyloid-β is particularly common and robust finding, especially within the thalamus [15,17,21]. Amyloid-β immunostaining in the thalamus often appears as a diffuse aggregation at 1-6 weeks (see Figure 2) and over time transforms into dense deposits at 9 months after stroke. Recently, our research team has reported the first evidence that the accumulation of amyloid-β observed within the thalamus after stroke is associated with enhancement of soluble amyloid-β oligomers [21]. Further, this enhancement of soluble amyloid-β oligomers is associated with loss of neurons within the thalamus after stroke [21], suggesting that the low and high molecular weight soluble amyloid-β configurations may be responsible for the cellular pathology [6,7,8]. Together, the rodent studies demonstrate that stroke can trigger amyloid deposition, most likely through interference in amyloid production or clearance pathways. Table 2 summarizes clinical and pre-clinical observation of amyloid-β accumulation in stroke-induced thalamic SND.
The pathology of SND after stroke typically develops in delayed manner similar to other neurodegenerative diseases, thus offering a wider therapeutic time window for stroke recovery. Over the last few years much effort has been made in pre-clinical/rodent studies targeting the "amyloid hypothesis" to ameliorate stroke-induced SND. These pre-clinical studies suggest that elimination of the neurotoxic protein itself may alleviate the loss of neurons leading to improvement in functional outcomes [52,53,54,55] and vice versa [21,56]. Table 3 summarizes pre-clinical studies on interventions which modulate thalamic amyloid-β accumulation after stroke.
There is now robust neuroimaging and histological data to support the existence of SND after stroke in both human and animal studies (see Table 1). The histopathological features of stroke-induced thalamic SND, the persistent loss of neurons and intense glial disturbance, clearly suggest that stroke triggers a neurodegenerative condition. In terms of linking this neurodegenerative response to the disturbances of amyloid-β, the rodent studies are very consistent, with accumulation of amyloid-β routinely being observed (see Table 2). Human studies of amyloid-β disturbances, however, are currently few in number. We could identify only four clear human studies examining amyloid-β levels after stroke, with one utilising histological staining [16] and the other three based on PET with [11C]PiB [18,20,30]. Aho et al. and Liu et al. reported clear signs of amyloid-β disturbance, whereas, Sahathevan et al. reported no obvious changes. Together, it would be unreasonable to propose that these human studies be taken to support or oppose significant disturbances in amyloid-β. Certainly, larger longitudinal studies are warranted. It is important to recognise that the [11C]PiB signal only provides information on amyloid fibrils and plaques, and not on non-fibril based amyloid-β disturbances [31] (see Figure 1). This is relevant as an increasing number of studies suggest that the non-fibrillar forms of amyloid-β, rather than the fibrils and plaques, are responsible for the disruption of cellular functions [6,7,8]. This is further supported by observation in rodent studies from our research team that accumulation of soluble amyloid-β oligomers is associated with neuron loss within the thalamus 6 weeks after stroke [21].
In summary, this short review has attempted to provide evidence that stroke is associated with neurodegeneration, characterised by progressive neuronal death accompanied by intense glial disturbance, and these phenomena occur in both humans and rodents. There is robust evidence concerning the presence of amyloid-β at sites of stroke-induced SND in rodent studies and preliminary evidence of same effect in human studies. Further, pre-clinical studies suggest that amyloid-β can be modulated at sites of stroke-induced SND to provide therapeutic benefit (see Table 3). More evidences from further clinical studies, especially non-human primate studies, are needed. This may provide a potential therapeutic direction for future clinical studies.
| Species | Stroke location/model | Method of measurement | Conclusion | Reference |
| Human | MCA infarction | CT | Thalamus gradually reduced in size 3-12 months after stroke. | Tamura et al., 1991 |
| Human | MCA infarction | MRI | Hypointensity in the thalamus at 1-12 months after stroke. | Ogawa et al., 1997 |
| Human | MCA infraction | MRI | Hypointensity in the thalamus 6 weeks after stroke. | Nakane et al., 2002 |
| Human | MCA infraction | DTI | Thalamus increased in mean diffusivity at 3 and 6 months after stroke. | Buffon et al., 2005 |
| Human | MCA infraction | DTI | Thalamus progressively increased in mean diffusivity at 1-6 months after stroke. | Herve et al., 2005 |
| Human | Corona radiata infarction | MRI and DTI | Thalamus increased in mean diffusivity at 12 weeks after stroke. | Li et al., 2011 |
| Human | MCA infarction | PET with [11C]PK11195, a marker of activated microglia | Persistently, increased tracer binding, suggesting microglia activation in the thalamus at 2 weeks-6 months after stroke. | Pappata et al., 2000 |
| Human | MCA infarction | PET with [11C]PK11195 | Thalamus increased in tracer intensity (microglia activation) at 28-150 days after stroke. | Gerhard et al., 2005 |
| Marmoset | MCA occlusion | Neuronal tracer injection | Decreased of labelled neurons in the thalamus at 45 days after stroke. | Bihel et al., 2010 |
| Rat | MCA occlusion | Area analysis with computer digitizer | Progressive shrinkage of the thalamus at 2 weeks-6 months after stroke. | Fujie et al., 1990 |
| Rat | MCA occlusion | Silver staining and IHC with GFAP, a marker of astrocytes | Loss of neurons and activation of astrocytes detected in the thalamus at 3 and 6 weeks after stroke. | Iizuka et al., 1990 |
| Rat | MCA occlusion or PT parietal cortex occlusion | Nissl staining and IHC with GFAP and OX-42 (a marker for microglia) | Enhanced glial activation detected in the thalamus at 1 day after stroke, preceded the reduction of neurons at 2 weeks. | Dihne et al., 2002 |
| Rat | MCA occlusion | MRI and IHC with NeuN, GFAP and OX-42 | Persistent hypointensity in the thalamus from 7 until 24 weeks after stroke. Neuronal loss in the thalamus accompanied by strong glial reactivity at 3 to 24 weeks after stroke. | Justicia et al., 2008 |
| Mouse | Somatosensory cortex ablation | Nissl staining and IHC with GFAP | Persistently, enhanced astrocytes activation detected in the thalamus at 2 days and up to 60 days after stroke, preceded the degeneration of neurons. | Ross & Ebner, 1990 |
| Mouse | PT somatosensory cortex occlusion | IHC with NeuN and various markers of microglia/monocytes (Iba1, CD11b, CD68 and MHC-Ⅱ) | Loss of neurons concomitant with intense activation of microglia/monocytes in the thalamus at 4 weeks after stroke. | Jones et al., 2015 |
| Mouse | PT somatosensory cortex occlusion | IHC with GFAP | Astrogliosis in the thalamus at 4 weeks after stroke. | Patience et al., 2015 |
| CT, computed tomography; DTI, diffusion tensor imaging; IHC, immunohistochemistry; MRI, magnetic resonance imaging; PET, positron emission tomographic; PT, photothrombotic. | ||||
DownLoad: CSV| Species | Stroke location/model | Method of measurement | Conclusion | Reference |
| Human | Cerebrovascular lesion (location not mentioned) | IHC with amyloid-β (Dako, M0872) | Amyloid-β accumulation was detected in the parietal cortex of 168 (34%) subjects and in the thalamus of 120 (25%) subjects (total 484 subjects). | Aho et al, 2006 |
| Human | Ischemic stroke (location not mentioned) | PET with [11C]PiB | [11C]PiB retention in the peri-infarct, but not the thalamus within 30 days after stroke (total 21 subjects). | Ly et al., 2012 |
| Marmoset | MCA occlusion | IHC with amyloid-β (Covance, 6E10) | Accumulation of amyloid-β in the peri-infarct and substantia nigra, but not the thalamus at 45 days after stroke (4 stroke subjects versus 2 controls). | Lipsanen et al., 2013 |
| Rat | MCA occlusion | IHC with amyloid-β (Signet, Aβ3-16) | Transformation of diffuse amyloid-β staining at 1 week after stroke to dense plaque-like deposits in the thalamus at 9 months. | van Groen et al., 2005 |
| Rat | MCA occlusion | IHC with amyloid-β (Covance, Aβ3-16) | Accumulation of amyloid-β in the thalamus at 26 weeks after stroke. | Makinen et al., 2008 |
| Mouse | PT somatosensory cortex occlusion | IHC and western blotting with amyloid-β (Cell signalling Technology, #15126) | Accumulation of amyloid-β which is associated with enhancement of soluble amyloid-β oligomers in the thalamus at 6 weeks after stroke. | Ong et al., 2016 |
DownLoad: CSV| Species | Stroke model | Intervention | Conclusion | Reference |
| Rat | MCA occlusion | Single oral administration of γ-secretase inhibitor, DAPT (50 mg/kg), at 3 days after stroke | DAPT treatment was associated with reduction of thalamic amyloid-β accumulation, attenuation of neuron loss and glial activation and improvement of sensory function at 7 days after stroke. | Zhang et al., 2011 |
| Rat | MCA occlusion | Daily oral administration of calcium channel blocker, beprildil (50 mg/kg), at 2 days after stroke | Beprildil treatment decreased soluble amyloid-β 40 and 42 in the thalamus and improved sensorimotor function at 29 days after stroke. | Sarajarvi et al., 2012 |
| Rat | MCA occlusion | Single intraventricular injection of autophagy inhibitor, 3-MA (600 nm), at 1 day after stroke | 3-MA treatment decreased thalamic amyloid-β accumulation and neuron loss at 7 and 14 days after stroke. | Zhang et al., 2012 |
| Rat | MCA occlusion | Single intraarterial infusion of BMMSC (1 × 106) at 2 or 7 days after stroke | BMMSC treatment elevated thalamic amyloid-β accumulation and impaired sensorimotor function. | Mitkari et al., 2015 |
| Mouse | PT somatosensory cortex occlusion | Chronic restraint stress at 3 days after stroke | Chronic stress exacerbated thalamic amyloid-β accumulation and neuron loss at 6 weeks after stroke. | Ong et al., 2016 |
| DAPT, N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester; 3-M, 3-methyladenine; BMMSC, bone marrow-derived mesenchymal stem cells. | ||||
DownLoad: CSVLKO, FRW and MN are supported by National Health and Medical Research Council (NHMRC) of Australia, University of Newcastle, Hunter Medical Research Institute and the NHMRC Centre for Research Excellence in Stroke Recovery and Rehabilitation.
All authors declare no conflict of interest.
| [1] |
Baron JC, Yamauchi H, Fujioka M, et al. (2014) Selective neuronal loss in ischemic stroke and cerebrovascular disease. J Cereb Blood Flow Metab 34: 2-18. doi: 10.1038/jcbfm.2013.188
|
| [2] |
Zhang J, Zhang Y, Xing S, et al. (2012) Secondary neurodegeneration in remote regions after focal cerebral infarction: a new target for stroke management? Stroke 43: 1700-1705. doi: 10.1161/STROKEAHA.111.632448
|
| [3] |
Levine DA, Galecki AT, Langa KM, et al. (2015) Trajectory of Cognitive Decline After Incident Stroke. JAMA 314: 41-51. doi: 10.1001/jama.2015.6968
|
| [4] |
Yang J, Wong A, Wang Z, et al. (2015) Risk factors for incident dementia after stroke and transient ischemic attack. Alzheimers Dement 11: 16-23. doi: 10.1016/j.jalz.2014.01.003
|
| [5] |
Querfurth HW, LaFerla FM (2010) Alzheimer's disease. N Engl J Med 362: 329-344. doi: 10.1056/NEJMra0909142
|
| [6] |
Caughey B, Lansbury PT (2003) Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26: 267-298. doi: 10.1146/annurev.neuro.26.010302.081142
|
| [7] | Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8: 101-112. |
| [8] |
Roychaudhuri R, Yang M, Hoshi MM, et al. (2009) Amyloid beta-protein assembly and Alzheimer disease. J Biol Chem 284: 4749-4753. doi: 10.1074/jbc.R800036200
|
| [9] | Giuffrida ML, Caraci F, De Bona P, et al. (2010) The monomer state of beta-amyloid: where the Alzheimer's disease protein meets physiology. Rev Neurosci 21: 83-93. |
| [10] |
Gilbert BJ (2013) The role of amyloid beta in the pathogenesis of Alzheimer's disease. J Clin Pathol 66: 362-366. doi: 10.1136/jclinpath-2013-201515
|
| [11] | Carrillo-Mora P, Luna R, Colin-Barenque L (2014) Amyloid beta: multiple mechanisms of toxicity and only some protective effects? Oxid Med Cell Longev 2014: 795375. |
| [12] |
Viola KL, Klein WL (2015) Amyloid beta oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. Acta Neuropathol 129: 183-206. doi: 10.1007/s00401-015-1386-3
|
| [13] | Bruggink KA, Muller M, Kuiperij HB, et al. (2012) Methods for analysis of amyloid-beta aggregates. J Alzheimers Dis 28: 735-758. |
| [14] |
Pryor NE, Moss MA, Hestekin CN (2012) Unraveling the early events of amyloid-beta protein (Abeta) aggregation: techniques for the determination of Abeta aggregate size. Int J Mol Sci 13: 3038-3072. doi: 10.3390/ijms13033038
|
| [15] |
van Groen T, Puurunen K, Maki HM, et al. (2005) Transformation of diffuse beta-amyloid precursor protein and beta-amyloid deposits to plaques in the thalamus after transient occlusion of the middle cerebral artery in rats. Stroke 36: 1551-1556. doi: 10.1161/01.STR.0000169933.88903.cf
|
| [16] |
Aho L, Jolkkonen J, Alafuzoff I (2006) Beta-amyloid aggregation in human brains with cerebrovascular lesions. Stroke 37: 2940-2945. doi: 10.1161/01.STR.0000248777.44128.93
|
| [17] |
Makinen S, van Groen T, Clarke J, et al. (2008) Coaccumulation of calcium and beta-amyloid in the thalamus after transient middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 28: 263-268. doi: 10.1038/sj.jcbfm.9600529
|
| [18] |
Ly JV, Rowe CC, Villemagne VL, et al. (2012) Subacute ischemic stroke is associated with focal 11C PiB positron emission tomography retention but not with global neocortical Abeta deposition. Stroke 43: 1341-1346. doi: 10.1161/STROKEAHA.111.636266
|
| [19] |
Lipsanen A, Kalesnykas G, Pro-Sistiaga P, et al. (2013) Lack of secondary pathology in the thalamus after focal cerebral ischemia in nonhuman primates. Exp Neurol 248: 224-227. doi: 10.1016/j.expneurol.2013.06.016
|
| [20] |
Sahathevan R, Linden T, Villemagne VL, et al. (2016) Positron Emission Tomographic Imaging in Stroke: Cross-Sectional and Follow-Up Assessment of Amyloid in Ischemic Stroke. Stroke 47: 113-119. doi: 10.1161/STROKEAHA.115.010528
|
| [21] | Ong LK, Zhao Z, Kluge M, et al. (2016) Chronic stress exposure following photothrombotic stroke is associated with increased levels of Amyloid beta accumulation and altered oligomerisation at sites of thalamic secondary neurodegeneration in mice. J Cereb Blood Flow Metab. |
| [22] |
Lesne S, Koh MT, Kotilinek L, et al. (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440: 352-357. doi: 10.1038/nature04533
|
| [23] |
Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 8: 595-608. doi: 10.15252/emmm.201606210
|
| [24] | Sheikh S, Safia, Haque E, et al. (2013) Neurodegenerative Diseases: Multifactorial Conformational Diseases and Their Therapeutic Interventions. J Neurodegener Dis 2013: 563481. |
| [25] |
Walsh DM, Klyubin I, Fadeeva JV, et al. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539. doi: 10.1038/416535a
|
| [26] |
Buell AK, Dobson CM, Knowles TP, et al. (2010) Interactions between amyloidophilic dyes and their relevance to studies of amyloid inhibitors. Biophys J 99: 3492-3497. doi: 10.1016/j.bpj.2010.08.074
|
| [27] |
Nesterov EE, Skoch J, Hyman BT, et al. (2005) In vivo optical imaging of amyloid aggregates in brain: design of fluorescent markers. Angew Chem Int Ed Engl 44: 5452-5456. doi: 10.1002/anie.200500845
|
| [28] |
Klunk WE, Engler H, Nordberg A, et al. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55: 306-319. doi: 10.1002/ana.20009
|
| [29] |
Cohen AD, Rabinovici GD, Mathis CA, et al. (2012) Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. Adv Pharmacol 64: 27-81. doi: 10.1016/B978-0-12-394816-8.00002-7
|
| [30] |
Liu W, Wong A, Au L, et al. (2015) Influence of Amyloid-beta on Cognitive Decline After Stroke/Transient Ischemic Attack: Three-Year Longitudinal Study. Stroke 46: 3074-3080. doi: 10.1161/STROKEAHA.115.010449
|
| [31] | Rowe CC, Villemagne VL (2011) Brain amyloid imaging. J Nucl Med 52: 1733-1740. |
| [32] |
Glass CK, Saijo K, Winner B, et al. (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140: 918-934. doi: 10.1016/j.cell.2010.02.016
|
| [33] |
Martin JB (1999) Molecular basis of the neurodegenerative disorders. N Engl J Med 340: 1970-1980. doi: 10.1056/NEJM199906243402507
|
| [34] | Kovacs GG (2016) Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision Medicine. Int J Mol Sci 17. |
| [35] |
Tamura A, Tahira Y, Nagashima H, et al. (1991) Thalamic atrophy following cerebral infarction in the territory of the middle cerebral artery. Stroke 22: 615-618. doi: 10.1161/01.STR.22.5.615
|
| [36] |
Ogawa T, Yoshida Y, Okudera T, et al. (1997) Secondary thalamic degeneration after cerebral infarction in the middle cerebral artery distribution: evaluation with MR imaging. Radiology 204: 255-262. doi: 10.1148/radiology.204.1.9205256
|
| [37] |
Nakane M, Tamura A, Sasaki Y, et al. (2002) MRI of secondary changes in the thalamus following a cerebral infarct. Neuroradiology 44: 915-920. doi: 10.1007/s00234-002-0846-3
|
| [38] |
Li C, Ling X, Liu S, et al. (2011) Early detection of secondary damage in ipsilateral thalamus after acute infarction at unilateral corona radiata by diffusion tensor imaging and magnetic resonance spectroscopy. BMC Neurol 11: 49. doi: 10.1186/1471-2377-11-49
|
| [39] |
Buffon F, Molko N, Herve D, et al. (2005) Longitudinal diffusion changes in cerebral hemispheres after MCA infarcts. J Cereb Blood Flow Metab 25: 641-650. doi: 10.1038/sj.jcbfm.9600054
|
| [40] |
Herve D, Molko N, Pappata S, et al. (2005) Longitudinal thalamic diffusion changes after middle cerebral artery infarcts. J Neurol Neurosurg Psychiatry 76: 200-205. doi: 10.1136/jnnp.2004.041012
|
| [41] |
Pappata S, Levasseur M, Gunn RN, et al. (2000) Thalamic microglial activation in ischemic stroke detected in vivo by PET and [11C]PK1195. Neurology 55: 1052-1054. doi: 10.1212/WNL.55.7.1052
|
| [42] |
Gerhard A, Schwarz J, Myers R, et al. (2005) Evolution of microglial activation in patients after ischemic stroke: a [11C](R)-PK11195 PET study. Neuroimage 24: 591-595. doi: 10.1016/j.neuroimage.2004.09.034
|
| [43] |
Thiel A, Heiss WD (2011) Imaging of microglia activation in stroke. Stroke 42: 507-512. doi: 10.1161/STROKEAHA.110.598821
|
| [44] |
Fujie W, Kirino T, Tomukai N, et al. (1990) Progressive shrinkage of the thalamus following middle cerebral artery occlusion in rats. Stroke 21: 1485-1488. doi: 10.1161/01.STR.21.10.1485
|
| [45] |
Iizuka H, Sakatani K, Young W (1990) Neural damage in the rat thalamus after cortical infarcts. Stroke 21: 790-794. doi: 10.1161/01.STR.21.5.790
|
| [46] |
Dihne M, Grommes C, Lutzenburg M, et al. (2002) Different mechanisms of secondary neuronal damage in thalamic nuclei after focal cerebral ischemia in rats. Stroke 33: 3006-3011. doi: 10.1161/01.STR.0000039406.64644.CB
|
| [47] |
Justicia C, Ramos-Cabrer P, Hoehn M (2008) MRI detection of secondary damage after stroke: chronic iron accumulation in the thalamus of the rat brain. Stroke 39: 1541-1547. doi: 10.1161/STROKEAHA.107.503565
|
| [48] |
Bihel E, Pro-Sistiaga P, Letourneur A, et al. (2010) Permanent or transient chronic ischemic stroke in the non-human primate: behavioral, neuroimaging, histological, and immunohistochemical investigations. J Cereb Blood Flow Metab 30: 273-285. doi: 10.1038/jcbfm.2009.209
|
| [49] |
Ross DT, Ebner FF (1990) Thalamic retrograde degeneration following cortical injury: an excitotoxic process? Neuroscience 35: 525-550. doi: 10.1016/0306-4522(90)90327-Z
|
| [50] |
Jones KA, Zouikr I, Patience M, et al. (2015) Chronic stress exacerbates neuronal loss associated with secondary neurodegeneration and suppresses microglial-like cells following focal motor cortex ischemia in the mouse. Brain Behav Immun 48: 57-67. doi: 10.1016/j.bbi.2015.02.014
|
| [51] |
Patience MJ, Zouikr I, Jones K, et al. (2015) Photothrombotic stroke induces persistent ipsilateral and contralateral astrogliosis in key cognitive control nuclei. Neurochem Res 40: 362-371. doi: 10.1007/s11064-014-1487-8
|
| [52] |
Hiltunen M, Makinen P, Peraniemi S, et al. (2009) Focal cerebral ischemia in rats alters APP processing and expression of Abeta peptide degrading enzymes in the thalamus. Neurobiol Dis 35: 103-113. doi: 10.1016/j.nbd.2009.04.009
|
| [53] |
Zhang Y, Xing S, Zhang J, et al. (2011) Reduction of beta-amyloid deposits by gamma-secretase inhibitor is associated with the attenuation of secondary damage in the ipsilateral thalamus and sensory functional improvement after focal cortical infarction in hypertensive rats. J Cereb Blood Flow Metab 31: 572-579. doi: 10.1038/jcbfm.2010.127
|
| [54] |
Sarajarvi T, Lipsanen A, Makinen P, et al. (2012) Bepridil decreases Abeta and calcium levels in the thalamus after middle cerebral artery occlusion in rats. J Cell Mol Med 16: 2754-2767. doi: 10.1111/j.1582-4934.2012.01599.x
|
| [55] |
Zhang J, Zhang Y, Li J, et al. (2012) Autophagosomes accumulation is associated with beta-amyloid deposits and secondary damage in the thalamus after focal cortical infarction in hypertensive rats. J Neurochem 120: 564-573. doi: 10.1111/j.1471-4159.2011.07496.x
|
| [56] |
Mitkari B, Kerkela E, Nystedt J, et al. (2015) Unexpected complication in a rat stroke model: exacerbation of secondary pathology in the thalamus by subacute intraarterial administration of human bone marrow-derived mesenchymal stem cells. J Cereb Blood Flow Metab 35: 363-366. doi: 10.1038/jcbfm.2014.235
|
| 1. | Natalia Egorova, Thijs Dhollander, Mohamed Salah Khlif, Wasim Khan, Emilio Werden, Amy Brodtmann, Pervasive White Matter Fiber Degeneration in Ischemic Stroke, 2020, 51, 0039-2499, 1507, 10.1161/STROKEAHA.119.028143 | |
| 2. | Natalia Egorova, Franziskus Liem, Vladimir Hachinski, Amy Brodtmann, Predicted Brain Age After Stroke, 2019, 11, 1663-4365, 10.3389/fnagi.2019.00348 | |
| 3. | Christos Tapeinos, Graphene‐Based Nanotechnology in Neurodegenerative Disorders, 2021, 1, 2699-9307, 2000059, 10.1002/anbr.202000059 | |
| 4. | Houman Kahroba, Bahman Ramezani, Hamid Maadi, Mohammad Reza Sadeghi, Hajar Jaberie, Fatemeh Ramezani, The role of Nrf2 in neural stem/progenitors cells: From maintaining stemness and self-renewal to promoting differentiation capability and facilitating therapeutic application in neurodegenerative disease, 2021, 65, 15681637, 101211, 10.1016/j.arr.2020.101211 | |
| 5. | Murielle G Kluge, Mahmoud Abdolhoseini, Katarzyna Zalewska, Lin Kooi Ong, Sarah J Johnson, Michael Nilsson, Frederick R Walker, Spatiotemporal analysis of impaired microglia process movement at sites of secondary neurodegeneration post-stroke, 2019, 39, 0271-678X, 2456, 10.1177/0271678X18797346 | |
| 6. | Alejandro F. De Nicola, Maria Meyer, Rachida Guennoun, Michael Schumacher, Hazel Hunt, Joseph Belanoff, E. Ronald de Kloet, Maria Claudia Gonzalez Deniselle, Insights into the Therapeutic Potential of Glucocorticoid Receptor Modulators for Neurodegenerative Diseases, 2020, 21, 1422-0067, 2137, 10.3390/ijms21062137 | |
| 7. | Zidan Zhao, Rebecca J. Hood, Lin Kooi Ong, Giovanni Pietrogrande, Sonia Sanchez Bezanilla, Kirby E. Warren, Marina Ilicic, Murielle G. Kluge, Clifford TeBay, Ole P. Ottersen, Sarah J. Johnson, Michael Nilsson, Frederick R. Walker, Exploring How Low Oxygen Post Conditioning Improves Stroke-Induced Cognitive Impairment: A Consideration of Amyloid-Beta Loading and Other Mechanisms, 2021, 12, 1664-2295, 10.3389/fneur.2021.585189 | |
| 8. | Sonia Sanchez-Bezanilla, N. David Åberg, Patricia Crock, Frederick R. Walker, Michael Nilsson, Jörgen Isgaard, Lin Kooi Ong, Growth Hormone Treatment Promotes Remote Hippocampal Plasticity after Experimental Cortical Stroke, 2020, 21, 1422-0067, 4563, 10.3390/ijms21124563 | |
| 9. | Sonia Sanchez-Bezanilla, Clifford TeBay, Michael Nilsson, Frederick R. Walker, Lin Kooi Ong, Visual discrimination impairment after experimental stroke is associated with disturbances in the polarization of the astrocytic aquaporin-4 and increased accumulation of neurotoxic proteins, 2019, 318, 00144886, 232, 10.1016/j.expneurol.2019.05.001 | |
| 10. | Alexei Verkhratsky, Qing Li, Sonia Melino, Gerry Melino, Yufang Shi, Can COVID-19 pandemic boost the epidemic of neurodegenerative diseases?, 2020, 15, 1745-6150, 10.1186/s13062-020-00282-3 | |
| 11. | Fubing Ouyang, Xinran Chen, Yonghong Chen, Jiahui Liang, Yicong Chen, Tao Lu, Weixian Huang, Jinsheng Zeng, Neuronal loss without amyloid‐β deposits in the thalamus and hippocampus in the late period after middle cerebral artery occlusion in cynomolgus monkeys, 2020, 30, 1015-6305, 165, 10.1111/bpa.12764 | |
| 12. | Sonia Sanchez-Bezanilla, Michael Nilsson, Frederick R. Walker, Lin Kooi Ong, Can We Use 2,3,5-Triphenyltetrazolium Chloride-Stained Brain Slices for Other Purposes? The Application of Western Blotting, 2019, 12, 1662-5099, 10.3389/fnmol.2019.00181 | |
| 13. | Sonia Sanchez-Bezanilla, Rebecca J Hood, Lyndsey E Collins-Praino, Renée J Turner, Frederick R Walker, Michael Nilsson, Lin Kooi Ong, More than motor impairment: A spatiotemporal analysis of cognitive impairment and associated neuropathological changes following cortical photothrombotic stroke, 2021, 0271-678X, 0271678X2110058, 10.1177/0271678X211005877 | |
| 14. | Zaynab Ahmad Mouhammad, Rupali Vohra, Anna Horwitz, Anna-Sophie Thein, Jens Rovelt, Barbara Cvenkel, Pete A. Williams, Augusto Azuara-Blanco, Miriam Kolko, Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?, 2022, 16, 1662-453X, 10.3389/fnins.2022.824054 | |
| 15. | Lin Kooi Ong, Beyond the Primary Infarction: Focus on Mechanisms Related to Secondary Neurodegeneration after Stroke, 2022, 23, 1422-0067, 16024, 10.3390/ijms232416024 | |
| 16. | Maria Raza Tokatli, Leuconoe Grazia Sisti, Eleonora Marziali, Lorenza Nachira, Maria Francesca Rossi, Carlotta Amantea, Umberto Moscato, Walter Malorni, Hormones and Sex-Specific Medicine in Human Physiopathology, 2022, 12, 2218-273X, 413, 10.3390/biom12030413 | |
| 17. | Madeleine Hinwood, Jenny Nyberg, Lucy Leigh, Sara Gustavsson, John Attia, Christopher Oldmeadow, Marina Ilicic, Thomas Linden, N David Åberg, Chris Levi, Neil Spratt, Leeanne M Carey, Michael Pollack, Sarah J Johnson, Georg Hans Kuhn, Frederick R Walker, Michael Nilsson, Do P2Y12 receptor inhibitors prescribed poststroke modify the risk of cognitive disorder or dementia? Protocol for a target trial using multiple national Swedish registries, 2022, 12, 2044-6055, e058244, 10.1136/bmjopen-2021-058244 | |
| 18. | Ali Aghajani Shahrivar, Zahra Khakpourian, Fatemeh Majdi, Sarvenaz Sobhani, Natalie Coleman-Fuller, Mina Gholami, Majid Motaghinejad, Hypothesized neuroprotective effect of minocycline against COVID-19-induced stroke and neurological dysfunction: possible role of matrix metalloprotease signaling pathway, 2022, 77, 1336-9563, 3027, 10.1007/s11756-022-01162-z | |
| 19. | Xiaohua Yang, Gaixia Zhang, Jai Prakash, Zhangsen Chen, Marc Gauthier, Shuhui Sun, Chemical vapour deposition of graphene: layer control, the transfer process, characterisation, and related applications, 2019, 38, 0144-235X, 149, 10.1080/0144235X.2019.1634319 | |
| 20. | Sonia Sanchez-Bezanilla, Daniel J. Beard, Rebecca J. Hood, N. David Åberg, Patricia Crock, Frederick R. Walker, Michael Nilsson, Jörgen Isgaard, Lin Kooi Ong, Jiu Chen, Growth Hormone Increases BDNF and mTOR Expression in Specific Brain Regions after Photothrombotic Stroke in Mice, 2022, 2022, 1687-5443, 1, 10.1155/2022/9983042 | |
| 21. | Natalia Egorova-Brumley, Mohamed Salah Khlif, Emilio Werden, Laura J. Bird, Amy Brodtmann, Grey and white matter atrophy 1 year after stroke aphasia, 2022, 4, 2632-1297, 10.1093/braincomms/fcac061 | |
| 22. | Fubing Ouyang, Zimu Jiang, Xinran Chen, Yicong Chen, Jiating Wei, Shihui Xing, Jian Zhang, Yuhua Fan, Jinsheng Zeng, Is Cerebral Amyloid-β Deposition Related to Post-stroke Cognitive Impairment?, 2021, 12, 1868-4483, 946, 10.1007/s12975-021-00921-5 | |
| 23. | Vicente Llorente, Pedro Velarde, Manuel Desco, María Victoria Gómez-Gaviro, Current Understanding of the Neural Stem Cell Niches, 2022, 11, 2073-4409, 3002, 10.3390/cells11193002 | |
| 24. | Mafalda Ferreira dos Santos, Catarina Roxo, Susana Solá, Oxidative-Signaling in Neural Stem Cell-Mediated Plasticity: Implications for Neurodegenerative Diseases, 2021, 10, 2076-3921, 1088, 10.3390/antiox10071088 | |
| 25. | Sarthak Kakar, James N. Smorenburg, Intranasal Administration of Chitosan-Nanoparticles Conjugated with Imipramine and its Effect on Stroke-Induced Secondary Neurodegeneration: A Research Protocol, 2021, 5, 1, 10.26685/urncst.296 | |
| 26. | Soraya Noorgaldi, Hamzeh Badeli Sarkala, Ayesheh Enayati, Vahid Khori, Gökhan Zengin, Mehrdad Jahanshahi, Neuroprotective effect of Potentilla reptans L. root in the rat brain global ischemia/reperfusion model, 2023, 0365-6233, 10.1002/ardp.202300363 | |
| 27. | Stefano Brunelli, Emilia Giannella, Mirko Bizzaglia, Domenico De Angelis, Giulia Maria Sancesario, Secondary neurodegeneration following Stroke: what can blood biomarkers tell us?, 2023, 14, 1664-2295, 10.3389/fneur.2023.1198216 | |
| 28. | Rebecca J. Hood, Sonia Sanchez‐Bezanilla, Daniel J. Beard, Ruslan Rust, Renée J. Turner, Shannon M. Stuckey, Lyndsey E. Collins‐Praino, Frederick R. Walker, Michael Nilsson, Lin Kooi Ong, Leakage beyond the primary lesion: A temporal analysis of cerebrovascular dysregulation at sites of hippocampal secondary neurodegeneration following cortical photothrombotic stroke, 2023, 0022-3042, 10.1111/jnc.16008 | |
| 29. | Gloria Patricia Baena-Caldas, Jie Li, Lina Pedraza, Supurna Ghosh, Andreas Kalmes, Frank C. Barone, Herman Moreno, A. Iván Hernández, Ken Arai, Neuroprotective effect of the RNS60 in a mouse model of transient focal cerebral ischemia, 2024, 19, 1932-6203, e0295504, 10.1371/journal.pone.0295504 | |
| 30. | А.Л. Арьев, Е.С. Лаптева, COVID-19 AS A TRIGGER FOR THE ONSET AND PROGRESSION OF NEURODEGENERATIVE PATHOLOGY PREDOMINANTLY IN ELDERLY AND SENILE POPULATION, 2024, 36, 15619125, 810, 10.34922/AE.2023.36.6.006 | |
| 31. | Carolina Ferreira, Pedro Vieira, Helena Sá, João Malva, Miguel Castelo-Branco, Flávio Reis, Sofia Viana, Polyphenols: immunonutrients tipping the balance of immunometabolism in chronic diseases, 2024, 15, 1664-3224, 10.3389/fimmu.2024.1360065 | |
| 32. | Ruslan Rust, Lina R Nih, Luca Liberale, Hao Yin, Mohamad El Amki, Lin Kooi Ong, Berislav V Zlokovic, Brain repair mechanisms after cell therapy for stroke, 2024, 0006-8950, 10.1093/brain/awae204 | |
| 33. | A’isyah Mohd Safien, Norhayati Ibrahim, Ponnusamy Subramaniam, Suzana Shahar, Normah Che Din, Aniza Ismail, Devinder Kaur Ajit Singh, Arimi Fitri Mat Ludin, Randomized Controlled Trials of a Psychosocial Intervention for Improving the Cognitive Function among Older Adults: A Scoping Review, 2021, 7, 2333-7214, 10.1177/23337214211025167 |
Figures(2) / Tables(3)
Lin Kooi Ong, Frederick Rohan Walker, Michael Nilsson. Is Stroke a Neurodegenerative Condition? A Critical Review of Secondary Neurodegeneration and Amyloid-beta Accumulation after Stroke[J]. AIMS Medical Science, 2017, 4(1): 1-16. doi: 10.3934/medsci.2017.1.1
| Species | Stroke location/model | Method of measurement | Conclusion | Reference |
| Human | MCA infarction | CT | Thalamus gradually reduced in size 3-12 months after stroke. | Tamura et al., 1991 |
| Human | MCA infarction | MRI | Hypointensity in the thalamus at 1-12 months after stroke. | Ogawa et al., 1997 |
| Human | MCA infraction | MRI | Hypointensity in the thalamus 6 weeks after stroke. | Nakane et al., 2002 |
| Human | MCA infraction | DTI | Thalamus increased in mean diffusivity at 3 and 6 months after stroke. | Buffon et al., 2005 |
| Human | MCA infraction | DTI | Thalamus progressively increased in mean diffusivity at 1-6 months after stroke. | Herve et al., 2005 |
| Human | Corona radiata infarction | MRI and DTI | Thalamus increased in mean diffusivity at 12 weeks after stroke. | Li et al., 2011 |
| Human | MCA infarction | PET with [11C]PK11195, a marker of activated microglia | Persistently, increased tracer binding, suggesting microglia activation in the thalamus at 2 weeks-6 months after stroke. | Pappata et al., 2000 |
| Human | MCA infarction | PET with [11C]PK11195 | Thalamus increased in tracer intensity (microglia activation) at 28-150 days after stroke. | Gerhard et al., 2005 |
| Marmoset | MCA occlusion | Neuronal tracer injection | Decreased of labelled neurons in the thalamus at 45 days after stroke. | Bihel et al., 2010 |
| Rat | MCA occlusion | Area analysis with computer digitizer | Progressive shrinkage of the thalamus at 2 weeks-6 months after stroke. | Fujie et al., 1990 |
| Rat | MCA occlusion | Silver staining and IHC with GFAP, a marker of astrocytes | Loss of neurons and activation of astrocytes detected in the thalamus at 3 and 6 weeks after stroke. | Iizuka et al., 1990 |
| Rat | MCA occlusion or PT parietal cortex occlusion | Nissl staining and IHC with GFAP and OX-42 (a marker for microglia) | Enhanced glial activation detected in the thalamus at 1 day after stroke, preceded the reduction of neurons at 2 weeks. | Dihne et al., 2002 |
| Rat | MCA occlusion | MRI and IHC with NeuN, GFAP and OX-42 | Persistent hypointensity in the thalamus from 7 until 24 weeks after stroke. Neuronal loss in the thalamus accompanied by strong glial reactivity at 3 to 24 weeks after stroke. | Justicia et al., 2008 |
| Mouse | Somatosensory cortex ablation | Nissl staining and IHC with GFAP | Persistently, enhanced astrocytes activation detected in the thalamus at 2 days and up to 60 days after stroke, preceded the degeneration of neurons. | Ross & Ebner, 1990 |
| Mouse | PT somatosensory cortex occlusion | IHC with NeuN and various markers of microglia/monocytes (Iba1, CD11b, CD68 and MHC-Ⅱ) | Loss of neurons concomitant with intense activation of microglia/monocytes in the thalamus at 4 weeks after stroke. | Jones et al., 2015 |
| Mouse | PT somatosensory cortex occlusion | IHC with GFAP | Astrogliosis in the thalamus at 4 weeks after stroke. | Patience et al., 2015 |
| CT, computed tomography; DTI, diffusion tensor imaging; IHC, immunohistochemistry; MRI, magnetic resonance imaging; PET, positron emission tomographic; PT, photothrombotic. | ||||
DownLoad: CSV| Species | Stroke location/model | Method of measurement | Conclusion | Reference |
| Human | Cerebrovascular lesion (location not mentioned) | IHC with amyloid-β (Dako, M0872) | Amyloid-β accumulation was detected in the parietal cortex of 168 (34%) subjects and in the thalamus of 120 (25%) subjects (total 484 subjects). | Aho et al, 2006 |
| Human | Ischemic stroke (location not mentioned) | PET with [11C]PiB | [11C]PiB retention in the peri-infarct, but not the thalamus within 30 days after stroke (total 21 subjects). | Ly et al., 2012 |
| Marmoset | MCA occlusion | IHC with amyloid-β (Covance, 6E10) | Accumulation of amyloid-β in the peri-infarct and substantia nigra, but not the thalamus at 45 days after stroke (4 stroke subjects versus 2 controls). | Lipsanen et al., 2013 |
| Rat | MCA occlusion | IHC with amyloid-β (Signet, Aβ3-16) | Transformation of diffuse amyloid-β staining at 1 week after stroke to dense plaque-like deposits in the thalamus at 9 months. | van Groen et al., 2005 |
| Rat | MCA occlusion | IHC with amyloid-β (Covance, Aβ3-16) | Accumulation of amyloid-β in the thalamus at 26 weeks after stroke. | Makinen et al., 2008 |
| Mouse | PT somatosensory cortex occlusion | IHC and western blotting with amyloid-β (Cell signalling Technology, #15126) | Accumulation of amyloid-β which is associated with enhancement of soluble amyloid-β oligomers in the thalamus at 6 weeks after stroke. | Ong et al., 2016 |
DownLoad: CSV| Species | Stroke model | Intervention | Conclusion | Reference |
| Rat | MCA occlusion | Single oral administration of γ-secretase inhibitor, DAPT (50 mg/kg), at 3 days after stroke | DAPT treatment was associated with reduction of thalamic amyloid-β accumulation, attenuation of neuron loss and glial activation and improvement of sensory function at 7 days after stroke. | Zhang et al., 2011 |
| Rat | MCA occlusion | Daily oral administration of calcium channel blocker, beprildil (50 mg/kg), at 2 days after stroke | Beprildil treatment decreased soluble amyloid-β 40 and 42 in the thalamus and improved sensorimotor function at 29 days after stroke. | Sarajarvi et al., 2012 |
| Rat | MCA occlusion | Single intraventricular injection of autophagy inhibitor, 3-MA (600 nm), at 1 day after stroke | 3-MA treatment decreased thalamic amyloid-β accumulation and neuron loss at 7 and 14 days after stroke. | Zhang et al., 2012 |
| Rat | MCA occlusion | Single intraarterial infusion of BMMSC (1 × 106) at 2 or 7 days after stroke | BMMSC treatment elevated thalamic amyloid-β accumulation and impaired sensorimotor function. | Mitkari et al., 2015 |
| Mouse | PT somatosensory cortex occlusion | Chronic restraint stress at 3 days after stroke | Chronic stress exacerbated thalamic amyloid-β accumulation and neuron loss at 6 weeks after stroke. | Ong et al., 2016 |
| DAPT, N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester; 3-M, 3-methyladenine; BMMSC, bone marrow-derived mesenchymal stem cells. | ||||
DownLoad: CSV| Species | Stroke location/model | Method of measurement | Conclusion | Reference |
| Human | MCA infarction | CT | Thalamus gradually reduced in size 3-12 months after stroke. | Tamura et al., 1991 |
| Human | MCA infarction | MRI | Hypointensity in the thalamus at 1-12 months after stroke. | Ogawa et al., 1997 |
| Human | MCA infraction | MRI | Hypointensity in the thalamus 6 weeks after stroke. | Nakane et al., 2002 |
| Human | MCA infraction | DTI | Thalamus increased in mean diffusivity at 3 and 6 months after stroke. | Buffon et al., 2005 |
| Human | MCA infraction | DTI | Thalamus progressively increased in mean diffusivity at 1-6 months after stroke. | Herve et al., 2005 |
| Human | Corona radiata infarction | MRI and DTI | Thalamus increased in mean diffusivity at 12 weeks after stroke. | Li et al., 2011 |
| Human | MCA infarction | PET with [11C]PK11195, a marker of activated microglia | Persistently, increased tracer binding, suggesting microglia activation in the thalamus at 2 weeks-6 months after stroke. | Pappata et al., 2000 |
| Human | MCA infarction | PET with [11C]PK11195 | Thalamus increased in tracer intensity (microglia activation) at 28-150 days after stroke. | Gerhard et al., 2005 |
| Marmoset | MCA occlusion | Neuronal tracer injection | Decreased of labelled neurons in the thalamus at 45 days after stroke. | Bihel et al., 2010 |
| Rat | MCA occlusion | Area analysis with computer digitizer | Progressive shrinkage of the thalamus at 2 weeks-6 months after stroke. | Fujie et al., 1990 |
| Rat | MCA occlusion | Silver staining and IHC with GFAP, a marker of astrocytes | Loss of neurons and activation of astrocytes detected in the thalamus at 3 and 6 weeks after stroke. | Iizuka et al., 1990 |
| Rat | MCA occlusion or PT parietal cortex occlusion | Nissl staining and IHC with GFAP and OX-42 (a marker for microglia) | Enhanced glial activation detected in the thalamus at 1 day after stroke, preceded the reduction of neurons at 2 weeks. | Dihne et al., 2002 |
| Rat | MCA occlusion | MRI and IHC with NeuN, GFAP and OX-42 | Persistent hypointensity in the thalamus from 7 until 24 weeks after stroke. Neuronal loss in the thalamus accompanied by strong glial reactivity at 3 to 24 weeks after stroke. | Justicia et al., 2008 |
| Mouse | Somatosensory cortex ablation | Nissl staining and IHC with GFAP | Persistently, enhanced astrocytes activation detected in the thalamus at 2 days and up to 60 days after stroke, preceded the degeneration of neurons. | Ross & Ebner, 1990 |
| Mouse | PT somatosensory cortex occlusion | IHC with NeuN and various markers of microglia/monocytes (Iba1, CD11b, CD68 and MHC-Ⅱ) | Loss of neurons concomitant with intense activation of microglia/monocytes in the thalamus at 4 weeks after stroke. | Jones et al., 2015 |
| Mouse | PT somatosensory cortex occlusion | IHC with GFAP | Astrogliosis in the thalamus at 4 weeks after stroke. | Patience et al., 2015 |
| CT, computed tomography; DTI, diffusion tensor imaging; IHC, immunohistochemistry; MRI, magnetic resonance imaging; PET, positron emission tomographic; PT, photothrombotic. | ||||
| Species | Stroke location/model | Method of measurement | Conclusion | Reference |
| Human | Cerebrovascular lesion (location not mentioned) | IHC with amyloid-β (Dako, M0872) | Amyloid-β accumulation was detected in the parietal cortex of 168 (34%) subjects and in the thalamus of 120 (25%) subjects (total 484 subjects). | Aho et al, 2006 |
| Human | Ischemic stroke (location not mentioned) | PET with [11C]PiB | [11C]PiB retention in the peri-infarct, but not the thalamus within 30 days after stroke (total 21 subjects). | Ly et al., 2012 |
| Marmoset | MCA occlusion | IHC with amyloid-β (Covance, 6E10) | Accumulation of amyloid-β in the peri-infarct and substantia nigra, but not the thalamus at 45 days after stroke (4 stroke subjects versus 2 controls). | Lipsanen et al., 2013 |
| Rat | MCA occlusion | IHC with amyloid-β (Signet, Aβ3-16) | Transformation of diffuse amyloid-β staining at 1 week after stroke to dense plaque-like deposits in the thalamus at 9 months. | van Groen et al., 2005 |
| Rat | MCA occlusion | IHC with amyloid-β (Covance, Aβ3-16) | Accumulation of amyloid-β in the thalamus at 26 weeks after stroke. | Makinen et al., 2008 |
| Mouse | PT somatosensory cortex occlusion | IHC and western blotting with amyloid-β (Cell signalling Technology, #15126) | Accumulation of amyloid-β which is associated with enhancement of soluble amyloid-β oligomers in the thalamus at 6 weeks after stroke. | Ong et al., 2016 |
| Species | Stroke model | Intervention | Conclusion | Reference |
| Rat | MCA occlusion | Single oral administration of γ-secretase inhibitor, DAPT (50 mg/kg), at 3 days after stroke | DAPT treatment was associated with reduction of thalamic amyloid-β accumulation, attenuation of neuron loss and glial activation and improvement of sensory function at 7 days after stroke. | Zhang et al., 2011 |
| Rat | MCA occlusion | Daily oral administration of calcium channel blocker, beprildil (50 mg/kg), at 2 days after stroke | Beprildil treatment decreased soluble amyloid-β 40 and 42 in the thalamus and improved sensorimotor function at 29 days after stroke. | Sarajarvi et al., 2012 |
| Rat | MCA occlusion | Single intraventricular injection of autophagy inhibitor, 3-MA (600 nm), at 1 day after stroke | 3-MA treatment decreased thalamic amyloid-β accumulation and neuron loss at 7 and 14 days after stroke. | Zhang et al., 2012 |
| Rat | MCA occlusion | Single intraarterial infusion of BMMSC (1 × 106) at 2 or 7 days after stroke | BMMSC treatment elevated thalamic amyloid-β accumulation and impaired sensorimotor function. | Mitkari et al., 2015 |
| Mouse | PT somatosensory cortex occlusion | Chronic restraint stress at 3 days after stroke | Chronic stress exacerbated thalamic amyloid-β accumulation and neuron loss at 6 weeks after stroke. | Ong et al., 2016 |
| DAPT, N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester; 3-M, 3-methyladenine; BMMSC, bone marrow-derived mesenchymal stem cells. | ||||
